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Preeclampsia is one of the most common adverse outcomes of pregnancy.1 The condition consists of new onset hyper-
tension and proteinuria in the second half of pregnancy but 
can also be superimposed on preexisting hypertension or renal 
disease. It is associated with increased risks of maternal and 
perinatal morbidity and mortality. A substantial proportion 
of severe adverse perinatal outcomes occur as a consequence 
of preterm birth because of preeclampsia, and a substantial 
proportion of adverse maternal outcomes occurs in severe 
preeclampsia.1
Preeclampsia is associated with an altered maternal pat-
tern of circulating placentally derived proteins regulating 
angiogenesis,2,3 such as sFlt-1 (soluble fms-like tyrosine 
kinase 1) and PlGF (placental growth factor). One of the 
simplest methods to quantify the pattern is to calculate the 
ratio between these 2 angiogenic factors in maternal serum. A 
recent study of women with clinically suspected disease dem-
onstrated that an sFlt-1:PlGF ratio cutoff of 38 provided clini-
cally useful prediction of the risk of preeclampsia.4 Higher 
sFlt-1:PlGF ratios, namely >85 at 28 weeks of gestational age 
(wkGA) and >110 at 36 wkGA, have been shown to be more 
strongly associated with the risk of preeclampsia.5 However, 
evidence for the diagnostic effectiveness of the ratio in screen-
ing women without clinical suspicion of the disease is poor. A 
meta-analysis published in 2015 concluded that further stud-
ies were required.6
Abstract—We sought to assess the ratio of sFlt-1 (soluble fms-like tyrosine kinase 1) to PlGF (placental growth factor) 
in maternal serum as a screening test for preeclampsia in unselected nulliparous women with a singleton pregnancy. 
We studied 4099 women recruited to the POP study (Pregnancy Outcome Prediction) (Cambridge, United Kingdom). 
The sFlt-1:PlGF ratio was measured using the Roche Cobas e411 platform at ≈20, ≈28, and ≈36 weeks of gestational 
age (wkGA). Screen positive was defined as an sFlt-1:PlGF ratio >38, but higher thresholds were also studied. At 28 
wkGA, an sFlt-1:PlGF ratio >38 had a positive predictive value (PPV) of 32% for preeclampsia and preterm birth, 
and the PPV was similar comparing women with low and high prior risk of disease. At 36 wkGA, an sFlt-1:PlGF 
ratio >38 had a PPV for severe preeclampsia of 20% in high-risk women and 6.4% in low-risk women. At 36 wkGA, 
an sFlt-1:PlGF ratio >110 had a PPV of 30% for severe preeclampsia, and the PPV was similar comparing low- and 
high-risk women. Overall, at 36 wkGA, 195 (5.2%) women either had an sFlt-1:PlGF ratio of >110 or an sFlt-1:PlGF 
ratio >38 plus maternal risk factors: 43% of these women developed preeclampsia, about half with severe features. 
Among low-risk women at 36 wkGA, an sFlt-1:PlGF ratio ≤38 had a negative predictive value for severe preeclampsia 
of 99.2%. The sFlt-1:PlGF ratio provided clinically useful prediction of the risk of the most important manifestations 
of preeclampsia in a cohort of unselected nulliparous women.  (Hypertension. 2017;69:731-738. DOI: 10.1161/
HYPERTENSIONAHA.116.08620.) • Online Data Supplement
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The aim of the present analysis was to evaluate the effec-
tiveness of the sFlt-1:PlGF ratio as a screening test for pre-
eclampsia in unselected nulliparous women recruited to the 
POP study (Pregnancy Outcome Prediction).7,8 Most of the 
participants were healthy because the cohort selection was 
solely based on nulliparity, singleton pregnancy, and the study 
catchment area. We analyzed the sFlt-1:PlGF ratio measured 
repeatedly at 20, 28, and 36 wkGA using the Roche Cobas 
e411 Elecsys immunoassay system, which has been certified 
by the Conformité Européenne mark for use as an in vitro 
medical device. Screen positive was defined on the basis of the 
previously described and validated cutoff of >38.4 We studied 
the most clinically important manifestations of preeclampsia, 
namely any severity of the disease leading to preterm birth or 
preeclampsia with severe features.
Methods
Study Design
The POP study was conducted at the Rosie Hospital, Cambridge, 
United Kingdom, as previously described.7,8 In brief, it was a pro-
spective cohort study of nulliparous women attending the hospital for 
their dating ultrasound scan between January 14, 2008 and July 31, 
2012 with a viable singleton pregnancy. The only clinical exclusion 
criterion was multiple pregnancy. The population was drawn from 
Cambridge and surrounding areas, with low rates of severe socio-
economic deprivation. Therefore, the cohort can be considered a 
population with low prior risk of disease and homogeneous from a 
socioeconomic perspective. Blood was obtained at the time of recruit-
ment (not analyzed in this study). Study participants attended the 
NIHR (National Institute for Health Research) Cambridge Clinical 
Research Facility at ≈20, ≈28, and ≈36 wkGA for blood sampling and 
ultrasound scans. Ethical approval was given by the Cambridgeshire 
2 Research Ethics Committee (reference number 07/H0308/163) and 
all participants provided written informed Consent.
Outcome Data
Outcome data were ascertained by review of each woman’s paper case 
record by research midwives and by record linkage to clinical elec-
tronic databases of ultrasonography (Astraia, Munchen, Germany), 
delivery (Protos; iSoft, Banbury, United Kingdom), biochemical tests 
(Meditech, Westwood, MA), and neonatal intensive care (Badgernet; 
Clevermed Ltd, Edinburgh, United Kingdom). Where preeclampsia 
was suspected on the basis of these data, there was a second review 
of the clinical case record to confirm the diagnosis and classifica-
tion (ie, with or without severe features) on the basis of the objec-
tive criteria of the 2013 ACOG Guideline (The American Congress 
of Obstetricians and Gynecologists; online-only Data Supplement).9 
Superimposed preeclampsia was defined as preeclampsia in women 
with preexisting renal disease or hypertension. Socioeconomic status 
was quantified using the Index of Multiple Deprivation,10 and birth 
weight percentiles were calculated using a population-based United 
Kingdom reference.11
Analysis Plan and Reporting
The definition of exposures, primary outcomes, secondary out-
comes, and sensitivity analyses were agreed in an analysis plan 
(online-only Data Supplement) before performing any analysis 
of the sFlt-1 and PlGF data. Analyses which were not predefined 
are identified as such. The primary outcome for the 20 wkGA 
measurement was a composite of (1) preeclampsia with deliv-
ery before 28 wkGA or (2) preeclampsia with delivery before 37 
wkGA where the onset of hypertension was before 28 wkGA. The 
primary outcome for the 28 wkGA measurement was preeclamp-
sia with delivery before 37 wkGA. The primary outcome for the 
36 wkGA measurement was preeclampsia with severe features 
(ie, preeclampsia with either severe hypertension or evidence of 
hepatic, renal, hematologic, cerebral, or pulmonary complications; 
online-only Data Supplement). Secondary outcomes are defined 
in the online-only Data Supplement. High risk of preeclamp-
sia was defined as either (1) maternal characteristics, using the 
UK National Institute for Health and Care Excellence Guideline 
(online-only Data Supplement)12 or (2) elevated 20 wkGA uterine 
artery Doppler, defined as a mean pulsatility index in the highest 
decile, as previously described.8 Family history of preeclampsia 
was not included in the definition of risk status because this infor-
mation was not available. The reporting of this study conforms to 
the STROBE (The Strengthening the Reporting of Observational 
Studies in Epidemiology) statement.
Samples and Immunoassays
Serum samples were collected as previously reported6 and stored at 
−80°C. All samples used in the current analysis had not previously 
been thawed before the day of analysis. Researchers performing the 
assays were blinded to the patients’ clinical information and preg-
nancy outcome. Maternal serum levels of sFlt-1 and PlGF were mea-
sured using Roche Elecsys assays on the electrochemiluminescence 
immunoassay platform, Cobas e411 (Roche Diagnostics). Using this 
system, the intra-assay coefficient of variation for human serum sam-
ples is <2% for sFlt-1 and PlGF, and the interassay coefficients of 
variation are 2.3% to 4.3% for the sFlt-1 assay and 2.7% to 4.1% for 
the PlGF assay. Screen positive was defined as sFlt-1:PlGF ratio of 
>38.4 We also studied more severe elevation of the ratio, namely, >85 
at 28 wkGA and >110 at 36 wkGA.5
Statistical Analysis
Full details of the statistical analysis are described in the Analysis 
plan (online-only Data Supplement). In brief, standard screening 
summary statistics were calculated from 2×2 tables. In addition, sFlt-
1:PlGF ratio was analyzed as a continuous variable using the area 
under the receiver operating characteristic curve (AUROCC). Time-
to-event analysis was performed where delivery with the given out-
come was the event and delivery without the outcome was treated as 
a competing risk, and this method was used to generate plots of the 
cumulative incidence of the outcome from the time of measurement. 
All analyses were performed using Stata 14.1.
Exclusions and Missing Data
Of the 4512 women recruited, 67 (1.5%) women withdrew and 233 
(5.2%) delivered elsewhere, leaving 4212 eligible women.8 Of these, 
5 (0.1%) did not have preeclampsia status available, and 108 (2.6%) 
did not have any sFlt-1:PlGF measurements available from the 28 or 
36 wkGA visits.
Results
Description of the Study Cohort
The study group consisted of 4099 women, of whom 3953 
had sFlt-1:PlGF measurement available from the 20 wkGA 
visit, 3989 from the 28 wkGA visit, and 3776 from the 36 
wkGA visit. The overall incidence of preeclampsia was 
6.5% (265/4099). The incidence of preterm preeclampsia 
with onset before 28 wkGA after the 20 wkGA measure-
ment was 0.10% (4/3953). The incidence of preeclampsia 
leading to preterm delivery following the 28 wkGA measure-
ment was 0.65% (26/3989). The incidence of delivery with 
severe preeclampsia after the 36 wkGA measurement was 
2.8% (106/3776). The characteristics of the cohort are tabu-
lated according to their experience of hypertensive complica-
tions of pregnancy (Table 1). In normotensive women, the 
median sFlt-1:PlGF ratios were 6.5, 2.7, and 11.2 at 20, 28, 
and 36 wkGA, respectively. The median ratio at 28 wkGA 
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Table 1. Characteristics of the Study Cohort (n=4099)
Characteristic
No Hypertensive 
Disorder Preterm Preeclampsia
Preeclampsia With 
Severe Features*
Preeclampsia Without 
Severe Features* Gestational Hypertension
n (%) 3751 (91.5) 26 (0.6) 111 (2.7) 128 (3.1) 83 (2.0)
Maternal characteristics
  Age, y 30 (27 to 33) 29 (25 to 34) 30 (26 to 34) 29 (26 to 33) 29 (25 to 33)
  Age stopped FTE, y 21 (18 to 23) 18 (16 to 21) 19 (17 to 22) 21 (18 to 23) 21 (17 to 22)
   Missing 105 (2.8) 1 (3.9) 4 (3.6) 7 (5.5) 5 (6.0)
  Height, cm 165 (161 to 170) 163 (158 to 167) 165 (160 to 168) 165 (161 to 168) 165 (160 to 168)
  Deprivation quartile
   1 (lowest) 917 (24) 7 (27) 26 (23) 27 (21) 20 (24)
   2 899 (24) 2 (7.7) 28 (25) 33 (26) 14 (17)
   3 897 (24) 12 (46) 26 (23) 28 (22) 21 (25)
   4 (highest) 889 (24) 5 (19) 28 (25) 34 (27) 18 (22)
   Missing 149 (3.7) 0 (0.0) 3 (2.7) 6 (4.7) 10 (12)
  Ethnicity
   Non-white 211 (5.6) 2 (7.7) 5 (4.5) 4 (3.1) 5 (6.0)
   White 3478 (93) 23 (88) 105 (95) 124 (97) 73 (88)
   Missing 62 (1.7) 1 (3.9) 1 (0.9) 0 (0.0) 5 (6.0)
  Married 2558 (68) 21 (81) 74 (67) 80 (63) 56 (67)
  Smoker 182 (4.9) 1 (3.9) 3 (2.7) 7 (5.5) 8 (9.6)
  Any alcohol consumption 172 (4.6) 0 (0.0) 4 (3.6) 4 (3.1) 6 (7.2)
   Missing 1 (<0.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
  Body mass index, kg/m2 24 (22 to 27) 28 (26 to 30) 25 (23 to 32) 28 (23 to 32) 27 (24 to 31)
   Missing 1 (<0.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
  Type 1 or type 2 DM 7 (0.2) 3 (12) 0 (0.0) 2 (1.6) 2 (2.4)
  Chronic hypertension 95 (2.5) 9 (35) 34 (31) 74 (58) 0 (0.0)
  Renal disease 28 (0.8) 1 (3.9) 3 (2.7) 8 (6.3) 0 (0.0)
  UtA mean PI highest decile 335 (8.9) 11 (42) 23 (21) 21 (16) 9 (11)
   Missing 91 (2.4) 2 (7.7) 1 (0.9) 7 (5.5) 3 (3.6)
Birth outcomes
  Birth weight, g 3425 (3110 to 3735) 2210 (1650 to 2660) 3425 (3050 to 3750) 3383 (3100 to 3785) 3501 (3190 to 3830)
  Birth weight, z score −0.15 (−0.71 to 0.41) −0.61 (−1.15 to 0.06) −0.14 (−0.73 to 0.63) −0.03 (−0.69 to 0.40) −0.15 (−0.59 to 0.71)
  Birth weight, centile 44 (24 to 66) 28 (13 to 52) 45 (23 to 73) 49 (25 to 66) 44 (28 to 76)
   Missing 1 (<0.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
  Gestational age, wk 40 (39 to 41) 35 (34 to 36) 40 (39 to 41) 40 (39 to 41) 40 (39 to 41)
  Induction of labor 1115 (30) 6 (23) 70 (63) 82 (64) 37 (45)
  Mode of delivery
   Spontaneous vaginal 1896 (51) 6 (23) 25 (23) 42 (33) 31 (37)
   Assisted vaginal 873 (23) 0 (0.0) 29 (26) 41 (32) 23 (28)
   Intrapartum cesarean 616 (16) 3 (12) 43 (39) 31 (24) 21 (25)
   Prelabor caesarean 356 (9.5) 17 (65) 13 (12) 14 (11) 8 (10)
   Missing 10 (0.3) 0 (0.0) 1 (0.9) 0 (0.0) 0 (0.0)
(Continued )
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was 6.5 (interquartile range, 3.4–22.5) in women who devel-
oped preterm preeclampsia, and the median ratio at 36 wkGA 
was 42.3 (interquartile range, 22.6–88.2) in women who had 
severe preeclampsia.
Screening Performance at 20 wkGA
None of the 4 women who experienced the primary outcome 
after the 20 wkGA measurement had an sFlt-1:PlGF ratio >38. 
The AUROCC for the sFlt-1:PlGF ratio was 0.70 (95% confi-
dence interval, 0.43–0.97; Figure 1A). Ten women had a ratio 
>38, and 1 woman had a ratio >85 at 20 wkGA. Further analy-
sis was not performed because of the small number of events.
Screening Performance at 28 wkGA
The AUROCC for the sFlt-1:PlGF ratio was 0.80 (95% con-
fidence interval, 0.70–0.89; Figure 1B). Women with an sFlt-
1:PlGF ratio >38 (n=19) had an incidence of preeclampsia 
leading to preterm delivery of 32% (Table 2). The positive pre-
dictive value (PPV) was similar in low- and high-risk women 
(33% versus 31%, respectively; P=0.91).
Screening Performance at 36 wkGA
The AUROCC for the sFlt-1:PlGF ratio was 0.81 (95% confidence 
interval, 0.77–0.86; Figure 1C). Women with an sFlt-1:PlGF 
ratio >38 (n=566) had an incidence of severe preeclampsia of 
10% (Table 2). The PPV was 20% in high-risk women and 6.4% 
in low-risk women. Among women with no prior risk factors, an 
sFlt-1:PlGF ratio ≤38 had a high negative predictive value for 
subsequent development of severe preeclampsia (>99%).
Analysis of Severe Elevation of the sFlt-
1:PlGF Ratio
We studied more severe elevation of the ratio, using pre-
defined thresholds, namely, 85 at 28 wkGA and 110 at 36 
sFlt-1:PlGF ratio
  At 20 wkGA 6.5 (4.4 to 9.4) 9.1 (5.1 to 15.9) 6.9 (5.0 to 9.1) 6.9 (4.5 to 10.6) 6.3 (4.2 to 8.4)
   Missing 125 (3.3) 4 (15) 6 (5.4) 7 (5.5) 4 (4.8)
  At 28 wkGA 2.7 (1.7 to 4.2) 6.5 (3.4 to 22.5) 3.9 (2.4 to 7.8) 3.9 (2.3 to 6.9) 2.6 (1.8 to 4.3)
   Missing 101 (2.7) 0 (0.0) 4 (3.6) 3 (2.3) 2 (2.4)
  At 36 wkGA 11.2 (5.1 to 22.6) 126.2 (64.5 to 187.7) 42.3 (22.6 to 88.2) 35.3 (18.4 to 65.3) 20.2 (8.2 to 38.3)
   Missing 274 (7.3) 20 (77) 9 (8.1) 11 (8.6) 9 (11)
Data are expressed as median (IQR) or n (column %) as appropriate. For fields where there is no category labeled missing, data were 100% complete. Maternal age 
was defined as age at recruitment. All other maternal characteristics were defined by self-report at the 20 wkGA interview, from examination of the clinical case record, 
or linkage to the hospital’s electronic databases. Deprivation was quantified using the Index of Multiple Deprivation 2007,10 which is based on census data from the 
area of the mother’s postcode. Birth weight percentiles and z scores were calculated using a population-based UK reference.11 Gestational hypertension was defined as 
development of hypertension in the second half of pregnancy in a previously normotensive woman who did not fulfill the diagnostic criteria for preeclampsia (online-only 
Data Supplement). DM indicates diabetes mellitus; FTE, full-time education; IQR, interquartile range; PI, pulsatility index; PlGF, placental growth factor; sFlt-1, soluble 
fms-like tyrosine kinase 1; UtA, uterine artery; and wkGA, weeks of gestational age.
*Confined to women delivering ≥37 wkGA.
Figure 1. Receiver operating characteristic curve analysis of the relationship between (A) sFlt-1 (soluble fms-like tyrosine kinase 1) to 
PlGF (placental growth factor) ratio at 20 weeks of gestational age (wkGA) and (1) preeclampsia with delivery before 28 wkGA or (2) 
preeclampsia with delivery before 37 weeks where the onset of hypertension was before 28 wkGA (n=4), (B) sFlt-1:PlGF at 28 wkGA and 
preeclampsia leading to preterm birth (n=26), and (C) sFlt-1:PlGF at 36 wkGA and severe preeclampsia (n=106). The continuous sFlt-
1:PlGF ratio is used, and the area under the receiver operating characteristic curve (AUROCC) with 95% confidence interval (CI) is given 
for each analysis.
Table 1. Continued
Characteristic
No Hypertensive 
Disorder Preterm Preeclampsia
Preeclampsia With 
Severe Features*
Preeclampsia Without 
Severe Features* Gestational Hypertension
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wkGA (Table 3). Only 7 women had an sFlt-1:PlGF ratio 
>85 at 28 wkGA. However, 4 out of 7 delivered preterm with 
a diagnosis of preeclampsia (PPV=57%). At 36 wkGA, 70 
women had an sFlt-1:PlGF ratio >110, and 21 developed 
severe preeclampsia (PPV=30%). The PPV was similar com-
paring women with and without prior risk factors (36% and 
24%, respectively).
Screening Performance at 36 wkGA Using 
the sFlt-1:PlGF Ratio Combined With Maternal 
Risk Factors
We then analyzed a composite definition of screen positive 
at 36 wkGA, namely, an sFlt-1:PlGF ratio of >110 irrespec-
tive of maternal risk factors or an sFlt-1:PlGF ratio >38 com-
bined with maternal risk factors. A total of 195 (5.2%) women 
screened positive by this definition and 43% of them subse-
quently delivered with a diagnosis of preeclampsia: 41 women 
(PPV=21%) developed preeclampsia with severe features, and 
43 (PPV=22%) developed preeclampsia without severe fea-
tures. The characteristics and outcomes for the 195 women are 
summarized (online-only Data Supplement).
Time-to-Event Analysis
We plotted the cumulative incidence of the primary outcomes 
after the 28 and 36 wkGA measurements of the sFlt-1:PlGF 
ratio using a competing risks model (Figure 2A and B). The 
36 wkGA measurements were stratified by maternal risk sta-
tus (Figure 2B). In both cases, the curves started to deviate at 
least 1 week after the time of measurement, and the propor-
tional increase in risk was maintained over the 7 to 8 weeks 
after the test. We also plotted the cumulative incidence of pre-
eclampsia for women at 36 wkGA with the composite defini-
tion of screen positive (Figure 2C), that is, a ratio >38 plus risk 
factors or a ratio of >110 irrespective of risk factors. Delivery 
without the primary outcome was treated as a competing risk 
in all 3 analyses. In all 3 plots, it is evident that >90% of the 
deliveries in the highest risk group occurred >1 week from the 
time of measurement of the ratio.
Discussion
The main finding of this study is that, in a cohort of 
unselected, first singleton pregnancies, measurement of the 
sFlt-1:PlGF ratio identified women with a high absolute risk 
Table 2. Screening Statistics for the Primary Outcomes by Maternal Risk Status Using the Threshold of sFlt-1:PlGF Ratio of >38 at 
28 and 36 wkGA
Screening Statistic (95% CI)
28 wkGA 36 wkGA
Preeclampsia With Preterm Delivery Preeclampsia With Severe Features
All High Risk Low Risk All High Risk Low Risk
Sensitivity (%) 23.1 (6.9–39.3) 22.2 (3.0–41.4) 25.0 (0.0–55.0) 54.7 (45.2–64.2) 53.3 (40.7–66.0) 56.5 (42.2–70.8)
Specificity (%) 99.7 (99.5–99.8) 98.8 (98.0–99.6) 99.9 (99.8–100.0) 86.2 (85.0–87.3) 80.6 (77.5–83.6) 87.4 (86.2–88.5)
Positive predictive value (%) 31.6 (10.7–52.5) 30.8 (5.7–55.9) 33.3 (0.0–71.1) 10.2 (7.7–12.7) 20.3 (14.0–26.5) 6.4 (4.0–8.7)
Negative predictive value (%) 99.5 (99.3–99.7) 98.2 (97.2–99.1) 99.8 (99.7–100.0) 98.5 (98.1–98.9) 94.9 (93.1–96.7) 99.2 (98.9–99.6)
Positive likelihood ratio* 70.3 (29.0–170.8) 18.6 (6.3–54.9) 200.6 (42.6–944.1) 4.0 (3.3–4.8) 2.7 (2.1–3.6) 4.5 (3.4–5.9)
Negative likelihood ratio† 0.77 (0.63–0.95) 0.79 (0.61–1.01) 0.75 (0.50–1.12) 0.53 (0.43–0.65) 0.58 (0.44–0.76) 0.50 (0.36–0.69)
CI indicates confidence interval; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase 1; and wkGA, weeks of gestational age (of measurement of 
the sFlt-1:PlGF ratio).
*Positive likelihood ratio was defined as the ratio between the proportions of screen positives among cases and screen positives among noncases ([S+|D+]/[S+|D−]).
†Negative likelihood ratio was defined as the ratio between the proportions of screen negatives among cases and screen negatives among noncases ([S−|D+]/
[S−|D−]). Raw data from 2×2 tables are shown in Tables S1 and S2 in the online-only Data Supplement.
Table 3. Screening Statistics for the Primary Outcomes by Maternal Risk Status Using the Threshold 
of sFlt-1:PlGF Ratio of >85 at 28 wkGA and >110 at 36 wkGA
Screening Statistic (95% CI)
28 wkGA 36 wkGA
Preeclampsia With 
Preterm Delivery Preeclampsia With Severe Features
All All High Risk Low Risk
Sensitivity (%) 15.4 (1.5–29.3) 19.8 (12.2–27.4) 20.0 (9.9–30.1) 19.6 (8.1–31.0)
Specificity (%) 99.9 (99.8–100.0) 98.7 (98.3–99.0) 96.8 (95.4–98.1) 99.1 (98.7–99.4)
Positive predictive value (%) 57.1 (20.5–93.8) 30.0 (19.3–40.7) 36.4 (20.0–52.8) 24.3 (10.5–38.1)
Negative predictive value (%) 99.4 (99.2–99.7) 97.7 (97.2–98.2) 92.9 (90.9–94.8) 98.8 (98.4–99.2)
Positive likelihood ratio 203.2 (47.8–863.3) 14.8 (9.2–23.8) 6.2 (3.2–11.9) 21.1 (10.6–42.2)
Negative likelihood ratio 0.85 (0.72–1.00) 0.81 (0.74–0.89) 0.83 (0.73–0.94) 0.81 (0.70–0.94)
CI indicates confidence interval; PlGF, placental growth factor; sFlt-1, soluble fms-like tyrosine kinase 1; and wkGA denotes 
weeks of gestational age (of measurement of the sFlt-1:PlGF ratio).  See Methods for definition of risk status and Tables S1 and 
S2 for raw data from 2×2 tables.
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of experiencing the clinically most important manifestations 
of preeclampsia. At 28 wkGA, an sFlt-1:PlGF ratio >38 iden-
tified women with a high risk (>30%) of subsequently deliver-
ing preterm with preeclampsia. Women who had a more severe 
elevation of the ratio (>85) had nearly 60% risk of delivering 
preterm with preeclampsia, whereas >99% of women who had 
a ratio of <38 did not develop the outcome. At 36 wkGA, ≈5% 
of women were identified as high risk on the basis of either 
an sFlt-1:PlGF ratio of >110 or an sFlt-1:PlGF ratio >38 plus 
maternal risk factors. Of this group, 43% were subsequently 
delivered with a diagnosis of preeclampsia, and about half of 
these cases were severe. Approximately 70% of women were 
identified as low risk at 36 wkGA, that is, they had no mater-
nal risk factors and an sFlt-1:PlGF ratio ≤38; their risk of 
developing severe preeclampsia was <1%.
Screening is generally only conducted when there are evi-
dence-based interventions which mitigate the risk. A key ele-
ment in the study design was to make a measurement close to 
term (36 wkGA), the rationale being that delivery is the main 
intervention to prevent preeclampsia. This can more easily and 
more safely be performed at term.13 Moreover, a randomized 
controlled trial has shown improved outcome after immedi-
ate induction of labor compared with expectant management 
in women with gestational hypertension or mild preeclampsia 
near term.14 In this study, we evaluated the diagnostic effec-
tiveness of the sFlt-1:PlGF ratio in identifying women at 
risk of developing preeclampsia. In light of our results, we 
hypothesize that one approach to reducing the burden of mor-
bidity associated with preeclampsia could be to screen nul-
liparous women at 36 wkGA using maternal risk factors and 
sFlt-1:PlGF ratio, monitor screen positive women closely, and 
perform induction of labor before the development of severe 
disease. This hypothesis could be readily tested in a random-
ized controlled trial evaluating whether the introduction of the 
screening test improves pregnancy outcome (clinical effec-
tiveness). Such an intervention is unlikely to cause harm, and 
we have recently demonstrated that routine induction of labor 
at 39 wkGA does not increase the risk of cesarean delivery or 
perinatal morbidity in another high-risk population of nullipa-
rous women, namely, those aged ≥35.15
The sFlt-1:PlGF ratio was also informative for the risk of 
preterm preeclampsia. Women with a ratio >38 at 28 wkGA 
had a 32% risk of preterm delivery with preeclampsia, and the 
ratio >38 had a high positive likelihood ratio (≈70). This may 
reflect the fact that this threshold represents much more signifi-
cant elevation at 28 wkGA (99.5th percentile) than 36 wkGA 
(85th percentile). However, the sensitivity of the sFlt-1:PlGF 
ratio >38 at 28 wkGA was only 23%. Although the POP study 
included mostly healthy women, this is consistent with the 
findings in women clinically suspected to have preeclampsia, 
where an elevated sFlt-1:PlGF ratio between 24 and 37 wkGA 
was also associated with an increased risk of developing the 
disorder within 4 weeks after the measurement.16 Hence, 
although the test provides clinically useful prediction of risk 
for a small proportion of women, the majority of women expe-
riencing the disease would not be identified using the test at 
28 wkGA. However, the AUROCC for the sFlt-1:PlGF ratio 
at 28 wkGA for preterm preeclampsia was 0.80. It is possible 
that combining the ratio with other measurements (clinical, 
Figure 2. Cumulative incidence of the primary outcomes 
(Methods) by sFlt-1 (soluble fms-like tyrosine kinase 1) to PlGF 
(placental growth factor) ratio: (A) sFlt-1:PlGF at 28 wkGA and 
preeclampsia leading to preterm birth, (B) sFlt-1:PlGF at 36 
wkGA and severe preeclampsia, stratified by maternal risk. 
High risk was defined on the basis of maternal risk factors or 20 
wkGA uterine artery Doppler (see Methods for details), and (C) 
composite risk status at 36 wkGA. Screen positive was defined 
as (1) sFlt-1:PlGF ratio of >38 and maternal risk factors or (2) sFlt-
1:PlGF ratio >110 irrespective of maternal risk factors. Screen 
negative was defined as all other women. Delivery without the 
given primary outcome was treated as a competing risk in all 3 
analyses. Hence, the maximum value of the cumulative incidence 
is the same as the positive predictive value, and the curve 
illustrates the distribution of the timing of the deliveries with the 
outcome in question.
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biomarker, and ultrasonic) in a multivariable model might pro-
vide better risk prediction. This is an area of further investi-
gation, which will be hopefully paralleled by studies aiming 
at the implementation of better treatment options. Currently, 
the main limitation of the clinical usefulness of the 28 wkGA 
measurement is the lack of a clearly effective intervention miti-
gating the risks for those who screen positive, other than close 
monitoring of the patient. Another important area for further 
study is to refine the estimation of risk in women whose 36 
wkGA assessment identified them as being at intermediate 
risk (5%–6%) of severe preeclampsia, namely, women with an 
sFlt-1:PlGF ratio >38 and no risk factors or risk factors but 
a ratio of ≤38. Possible approaches include identifying other 
informative biomarkers or repeating measurement of the sFlt-
1:PlGF ratio after 36 wkGA.
This study had many methodological strengths over previ-
ous studies. First, the size was sufficiently large that we were 
able to study the variants of preeclampsia associated with the 
most severe complications. Second, we used a clinically vali-
dated assay where the definition of screen positive was based 
on prior studies which had identified and validated the chosen 
threshold. Moreover, the sFlt-1:PlGF ratio can be calculated 
without modeling in relation to gestational age or maternal 
characteristics, and in this study, clinical care was provided 
without knowledge of the test result. Finally, the analyses in 
this study were planned and specified in advance.
A large-scale study on screening women using the sFlt-1: 
PlGF ratio has recently been reported.17 However, their findings 
are difficult to compare to this study because they pooled the 
results from a wide range of gestational ages (30–37 wkGA). 
Moreover, almost half of their population consisted of multipa-
rous women who had not previously experienced preeclampsia, 
and this is a group with a very low prior risk of disease. The 
PPV of a test depends both on the a priori risk and the positive 
likelihood ratio. It is difficult to interpret a summary estimate 
of PPV when almost half the population has a very low prior 
risk of the outcome. Another large study based on a multiethnic 
cohort of nulliparous women and high-risk parous women con-
cluded that angiogenic biomarkers measured in the first half of 
pregnancy performed poorly for predicting later development 
of preeclampsia.18 They also observed, however, that the mea-
surements became more strongly predictive when made closer 
to disease onset, but the analyses of late pregnancy data were 
limited by high rates of missing biomarker data (20%–30%). 
The focus of this study on nulliparous women was purposeful. 
One of the strongest clinical predictors of the risk of preeclamp-
sia is whether a woman has a previous history of pregnancy 
affected by the condition. This information dominates risk pre-
diction in multiparous women but is necessarily absent among 
nulliparous women. Another purposeful feature of the design 
of this study was measurement of biomarkers throughout ges-
tation. Results reported in the current and previous studies13 
suggest that screening tests for pregnancy complications have 
a better predictive value when performed close to disease onset.
Many studies have evaluated trying to predict preeclampsia 
solely using measurements made in the first trimester. Statistical 
models are used to determine prior risk. Further modeling is used 
to process values of first trimester uterine artery Doppler flow 
velocimetry and to convert first trimester protein concentrations 
into gestational age-corrected multiples of the median. Two 
models were externally evaluated in a prospective cohort study 
in Norway, where measurements were performed between 11 
and 14 wkGA.19 A study-derived threshold (10% false-positive 
rate) yielded PPVs of 5% to 12%, a sensitivity of 40% and posi-
tive likelihood ratios of 1.5 to 3.6 for all preeclampsia cases. 
Although the nature of that study does not allow direct compari-
son with this analysis, the current approach may be more likely 
to be clinically applicable, given that (1) the definition of screen 
positive was externally defined, (2) the PPVs were higher, (3) the 
outcome was confined to the clinically most significant cases, 
and (4) the handling of clinical and biochemical predictors is 
simpler.
Perspectives
We conclude that measurement of the sFlt-1:PlGF ratio at 36 
wkGA, combined with maternal risk factors, provides clini-
cally useful prediction of the risk of preeclampsia at term for ≈3 
quarters of unselected nulliparous women, identifying 5% of 
them as high risk and 70% as low risk. Screening the pregnant 
nulliparous population in late pregnancy using this measure-
ment could plausibly improve maternal and perinatal outcome 
when coupled with close monitoring and induction of labor, 
and this would be an appropriate focus for future randomized 
controlled trials. Women with extreme elevation of the ratio at 
28 wkGA have high absolute risks of preterm disease, and the 
test may be useful to identify women for the evaluation of can-
didate disease-modifying therapies as they become available.
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What Is New?
Among a population of nulliparous women at mixed risk of disease:
•	An sFlt-1 (soluble fms-like tyrosine kinase 1) to PlGF (placental growth 
factor) ratio >38 at 28 weeks of gestational age identified women with a 
high risk (>30%) of subsequently delivering preterm with preeclampsia.
•	An sFlt-1:PlGF ratio >110 at 36 weeks of gestational age identified 
women with a high risk (>30%) of subsequently experiencing severe 
preeclampsia.
•	An sFlt-1:PlGF ratio between >38 and <110 at 36 weeks of gestational 
age was only associated with a high absolute risk (>20%) of subse-
quently experiencing severe preeclampsia if the mother had additional 
risk factors.
What Is Relevant?
•	Measurement of the sFlt-1:PlGF ratio provides clinically useful informa-
tion on risk of the most clinically important manifestations of preeclamp-
sia among women having first pregnancies.
•	This identifies potential new approaches to trials of screening and in-
tervention.
Summary
Very high elevation of the sFlt-1:PlGF ratio identifies women with 
high absolute risks of preterm or severe preeclampsia, and moder-
ate elevation is informative of risk when combined with maternal 
risk factors.
Novelty and Significance
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Supplemental Methods 
Diagnosis of preeclampsia (based on the 2013 ACOG Guideline (PMID 24150027)) 
 
Hypertension, for the purposes of diagnosis of preeclampsia, was defined as one or more of the 
following: 
 2x diastolic blood pressure (DBP) >89 mmHg at least 4 hours apart  
 1x DBP >89 mmHg + (new antihypertensive treatment AND/OR magnesium sulphate)  
 1x DBP>109 mmHg 
 2x systolic blood pressure (SBP) >139 mmHg at least 4 hours apart  
 1x SBP >139 mmHg + (new antihypertensive treatment AND/OR magnesium sulphate)  
 1x SBP >159 mmHg 
 
Severe hypertension, for the purposes of diagnosis of preeclampsia with severe features, was 
defined as any one of the following: 
 2x DBP >109 mmHg at least 4 hours apart 
 2x SBP >159 mmHg at least 4 hours apart  
 1x DBP >109 mmHg + (new antihypertensive Rx AND/OR magnesium sulphate)  
 1x SBP >159 mmHg + (new antihypertensive Rx AND/OR magnesium sulphate)  
 
Proteinuria was defined as one or more of the following: 
 Greater than or equal to 300 mg per L in a 24 hour urine collection  
 2x dipstick reading of 1+ or greater 4 hours apart at >20 weeks gestational age 
 
Low platelets was defined as: 
 Platelets <100 at ≥ 24 weeks gestational age up to 48h after delivery in a woman with 
normal levels (>150) <20 weeks 
 
Elevated creatinine was defined as: 
 Creatinine >99mmol/L at ≥ 24 weeks gestational age up to 48h after delivery in women with 
normal levels or unrecorded <20 weeks. If the first onset of the hypertension was after 
delivery measurements up to 7d after birth were included in the definition. 
 
Elevated alanine transaminase (ALT) was defined as: 
 ALT >49 at ≥ 24 weeks gestational age up to 48h after delivery in a woman with normal 
levels or unrecorded <20 weeks 
 
Pulmonary oedema was defined on the basis of whether it was documented as being present when 
reviewing the paper case record 
  
Severe cerebral or visual disturbance was defined as: 
 Severe cerebral or visual disturbance documented in the paper case record, plus evidence of 
significant clinical concern, including 2 or more measures of uric acid 
 
Preeclampsia was defined as:  
 Hypertension (defined above) AND (Proteinuria AND/OR low platelets AND/OR elevated ALT 
AND/OR elevated creatinine AND/OR pulmonary oedema AND/OR severe cerebral/visual 
symptoms) 
 
Preeclampsia with severe features was defined as:  
 Preeclampsia AND (severe hypertension AND/OR low platelets AND/OR elevated ALT 
AND/OR elevated creatinine AND/OR pulmonary oedema AND/OR severe cerebral/visual 
symptoms) 
 
Gestational hypertension (GH) was defined as hypertension (as above) but not preeclampsia in a 
woman who was not hypertensive prior to 20 weeks and had no history of renal disease or essential 
hypertension. 
 
Severe gestational hypertension was defined as GH AND severe hypertension 
 
Pre-existing hypertension was defined as: 
 Record of any documented history of essential hypertension or documented past or present 
use of anti-hypertensives when booking for antenatal care AND/OR any DBP>89 prior to 20 
weeks gestational age AND/OR any SBP>139 prior to 20 weeks gestational age 
 
Pre-existing renal disease was defined as: 
 Record of any documented history of renal disease AND/OR heavy proteinuria prior to 20 
weeks 
 
Super-imposed preeclampsia 
 If there is pre-existing hypertension or renal disease, then preeclampsia is defined as super-
imposed. Diagnosis of superimposed preeclampsia required either new proteinuria or 
evidence of systemic involvement. 
 
Analysis plan 
Analysis plan for assessing the diagnostic effectiveness of the sFlt-1/PlGF ratio as a screening test 
for pre-eclampsia in the Pregnancy Outcome Prediction study (PMID 19019223 & 26360240). 
 
1.1 Defining exposure 
An existing study, PROGNOSIS (Hund et al, PMID 25230734), has evaluated the predictive value of 
knowing the Elecsys sFlt-1/PlGF immunoassay ratio in women with suspected pre-eclampsia (Zeisler 
et al, PMID 26735990). In that study, the ratio was treated as elevated when the value was >38 
(ruling in preeclampsia within 4 weeks). We will examine the relationship between measurements 
above and below this threshold and the risk of pre-eclampsia using blood samples collected from a 
prospective cohort of nulliparous women, conducted in Cambridge, UK, namely, the  Pregnancy 
Outcome Prediction study (PMID 19019223 & 26360240). The analysis will focus on three time 
points of measurement of the sFlt-1/PlGF ratio: (i) at ~20 weeks, (ii) at ~28 weeks, and (iii) at ~36 
weeks. We will also evaluate the screening properties of greater elevation of the ratio (>85 at 20 & 
28 weeks and >110 at 36 weeks) which have been previously described as diagnostic for pre-
eclampsia (Stepan et al, PMID 25736847). 
 
1.2 Defining outcome 
All definitions of outcome will be as per the 2013 ACOG classification (PMID 24150027). Super-
imposed pre-eclampsia is defined as pre-eclampsia in women with previous renal disease or 
hypertension. "Severe" is defined in the ACOG Guideline.  
  
1.3 Primary and secondary outcomes 
 1.3.1 The sFlt-1/PlGF ratio at ~20 weeks 
The primary outcome for the 20 week measurement is pre-eclampsia with delivery prior to 28 weeks 
or pre-eclampsia with delivery prior to 37 weeks and where the onset of hypertension was prior to 
28 weeks. 
1.3.2 The sFlt-1/PlGF ratio at ~28 weeks 
The primary outcome for the 28 week measurement is pre-eclampsia with delivery prior to 37 
weeks. Secondary outcomes for the 28 week measurement are (a) pre-eclampsia, with onset of 
hypertension prior to 37 weeks, (b) gestational hypertension, with delivery prior to 37 weeks, (c) 
gestational hypertension, with onset of hypertension prior to 37 weeks, (d) either pre-eclampsia or 
gestational hypertension with onset of hypertension prior to 37 weeks.  
1.3.3 The sFlt-1/PlGF ratio at ~36 weeks 
The primary outcome for the 36 week measurement is pre-eclampsia with severe features. 
Secondary outcomes for the 36 week measurement are (a) pre-eclampsia without severe features, 
(b) severe gestational hypertension, (c) gestational hypertension, (d) either pre-eclampsia or 
gestational hypertension.  
1.3.4 Sensitivity analyses 
1.3.4.1 We will compare associations between super-imposed pre-eclampsia and pre-eclampsia in 
women without prior hypertension or renal disease.  
1.3.4.2 We will also compare the predictive ability of the test, stratifying the cohort on the basis of 
being at high risk of pre-eclampsia. This will be defined on the basis of maternal characteristics 
(using the NICE Guideline recommendation of 2 moderate or 1 high risk factor) or the 20 week 
uterine artery Doppler (defined as a mean pulsatility index >90th percentile). 
1.3.4.3 At each time point (20, 28 or 36 weeks), we will also analyse associations based on the 
previous measurement (i.e. 12, 20 or 28 weeks, respectively). We will then determine whether the 
associations between the outcomes and the sFlt-1/PlGF ratio differ according to the trend of 
increasing or decreasing value. Low will be defined as <38, moderate as 38-85/110 (depending on 
GA), and high as >85 at 20 or 28 weeks, or >110 at 36 weeks. 
 
1.4 Analytic approach 
Analysis will be performed using 2x2 tables and calculation of standard screening summary statistics 
(sensitivity, specificity, positive predictive value, negative predictive value, and positive and negative 
likelihood ratios). We will also describe the association between pre-eclampsia and the sFlt-1/PlGF 
ratio as a continuous variable by plotting the receiver operating characteristic (ROC) curve and 
estimating the c statistic (= the area under the ROC curve). We will perform analyses for a ratio of 
>38 ruling in pre-eclampsia, and a ratio of <38 for ruling out pre-eclampsia. We will repeat the 
analysis for severe elevation of the ratio (>85 at 20 or 28 weeks, or >110 at 36 weeks). 
 
Finally, we will analyse by time to event methods, i.e. a Kaplan-Meier plot of cumulative incidence of 
pre-eclampsia from time of measurement, and use a Cox model to generate HR for subsequent 
diagnosis with pre-eclampsia. We may also use time to event methods that account for competing 
risks (Akolekar et al, 2013, PMID 22906914). We will use these methods to perform secondary 
analyses of screening performance to rule in/out pre-eclampsia for 1, 2, 4 and 6 weeks. 
 
1.5 Exploratory analyses 
We will compare the predictive ability of the ratio using ROC curve analyses for different phenotypes 
of pre-eclampsia, specifically, associated with (i) maternal renal dysfunction, (ii) HELLP syndrome, or 
(iii) fetal growth restriction. 
We will also determine the relationship between the risk of pre-eclampsia and the trend of the level 
of the sFlt-1/PlGF ratio (i.e. increasing or decreasing) treating the ratio as a continuous variable and 
modelling the change across gestation. 
 
1.6 Presentation of results. 
In the publication, primary and secondary outcomes will be defined as above. Any analyses not 
described above will be clearly identified as not part of the original analysis plan. 
 
1.7 Statement 
The above plan was drawn up prior to any analysis of the relationship between sFlt-1, PlGF, or the 
ratio of sFlt-1/PlGF and the maternal risk of pre-eclampsia in the Pregnancy Outcome Prediction 
study. 
 
Missing data 
Of 4,512 women recruited to the study, we excluded 300 (6.6%) women who were not eligible, 5 
(0.1%) who did not have preeclampsia status available and 108 (2.6%) who did not have any sFlt-
1:PlGF measurements available from the 28 or 36 week visits. 
Trend analyses 
Change in the sFlt-1:PlGF ratio was defined as the change in the measurement between the 28 and 
36 week visits divided by the time difference between the measurements in weeks. The association 
between the change in the sFlt-1:PlGF ratio was quantified using the c statistic. We then determined 
whether the associations between the primary outcome and the sFlt-1:PlGF ratio differed according 
to the trend of increasing value, which was analysed in tertiles to ensure an adequate number of 
cases in each stratum.  
Supplemental Results 
Missing data 
Among the 4,099 women included in the study population, 3,953 had sFlt-1:PlGF measurement 
available from the 20 week visit, 3,989 from the 28 week visit and 3,776 from the 36 week visit. 
Among the variables used for defining risk status based on maternal characteristics, the proportion 
of missing values was low (105/4,099 = 2.6% in total, including 104 missing values in UtA PI from the 
20 week visit and one missing value in BMI from the 12 week visit). We replaced them with the most 
common value for the purpose of defining high risk of preeclampsia in the entire study population, 
i.e. UtA PI ≤90th percentile and BMI<35 kg/m2. 
Descriptive statistics 
Overall, 81% of the women were classified into the low risk and 19% were classified into the high risk 
category, based on maternal characteristics without considering the sFlt-1:PlGF measurement. Raw 
data on screening for the primary outcomes by maternal risk status using different thresholds is 
given in Tables S1 and S2. 
A total of 195 women were screen positive using a composite definition at 36wkGA (sFlt-1:PlGF ratio 
>110 irrespective of maternal risk factors or sFlt-1:PlGF ratio >38 with maternal risk factors).  Their 
characteristics and outcomes are summarized in Table S3.  
In total, 21 cases of severe preeclampsia had sFlt-1:PlGF ratio >110 at 36wkGA, and 32 cases had 
sFlt-1:PlGF ratio >38 and maternal risk factors. Twelve of these overlap (20 women had maternal risk 
factors and sFlt-1/PlGF ratio between 38 and 110, and 9 women had sFlt-1/PlGF ratio >110 but no 
maternal risk factors).   
A total of 2,660 women were screen negative using a definition of sFlt-1:PlGF ratio of ≤38 and the 
absence of maternal risk factors. Their characteristics and outcomes are summarized in Table S4. 
Of the 106 women who had pre-eclampsia with severe features, 72 had proteinuria, 69 had 
abnormal blood results (including 43 elevated creatinine, 30 elevated ALT and 18 low platelets), 67 
had severe hypertension, ten had severe cerebral or visual disturbances and two had pulmonary 
oedema. The overlap of five of these features including blood abnormalities, hypertension and 
severe cerebral/visual disturbances has been described using a Venn diagram (Figure S1).  
Model performance 
For the 28wkGA and 36wkGA measurements, the area under the ROC curve (AUROCC) was similar 
regardless of the maternal risk status (Figures S2 and S3). The model performance was generally 
weaker for the secondary outcomes (Figures S4 and S5). When the primary outcomes were 
compared according to whether the preeclampsia was superimposed on prior hypertension or renal 
disease, the AUROCC was ~0.8 in all analyses (Figures S6 and S7). No further analysis was performed 
using the 20wkGA measurement due to small number of events. 
Of the secondary outcomes, gestational hypertension leading to preterm birth was strongly 
associated with the continuous sFlt-1:PlGF ratio at 28wkGA (Table S5). The association between the 
ratio measured at 36wkGA and any gestational hypertension was much weaker (AUROCC = 0.88 vs. 
0.62, respectively). 
Finally, the associations were analysed by phenotype of preeclampsia. The number of cases was 
small in the analysis of the sFlt-1:PlGF ratio and preeclampsia with renal dysfunction (n=1) or HELLP 
syndrome (n=2) leading to preterm birth (Figure S8). The sFlt-1:PlGF ratio at 36wkGA was strongly 
associated with preeclampsia combined with HELLP syndrome but not with preeclampsia combined 
with renal dysfunction (Figure S9). 
Trend analyses 
The primary outcome at 36wkGA was additionally analysed in relation to change in the sFlt-1:PlGF 
ratio between 28 and 36 week visit. A total of 3,666 women had both measurements available. The 
median change was 1.11 (IQR 0.35-2.67) per wkGA. The change in the sFlt-1:PlGF ratio was highly 
correlated with the sFlt-1:PlGF ratio at 36wkGA (spearman correlation coefficient = 0.98). The 
variation in the ratio at 36wkGA was much larger than at 28wkGA, and the change in the ratio was 
driven by the 36wkGA measurement. Therefore, its association with the primary outcome at 
36wkGA was very similar: the c statistic was 0.82 (95% CI 0.77–0.86). We did not observe substantial 
differences in the associations between the primary outcome and the sFlt-1:PlGF ratio according to 
the trend of increasing value although the c statistic was slightly higher in the highest tertile (Table 
S6).  
Proximity of measurement and the risk of preeclampsia 
We performed an analysis not described in the analysis plan to determine the relationship between 
the timing of screening and the strength of association with preeclampsia. In order to allow 
comparison of measurements made at different gestational ages, we studied the top decile of sFlt-
1:PlGF ratio using the distribution of values observed in this study. The risk of preeclampsia resulting 
in preterm birth was increased in women with values of the ratio in the top decile at both 20wkGA 
and 28wkGA (Figure S10). However, the association was stronger for measurement at 28wkGA. Top 
decile of the sFlt-1:PlGF ratio at 20wkGA was not associated with the risk of preeclampsia with 
severe features at or near term but there were associations with both the 28wkGA and 36wkGA 
measurements. However, the association was stronger at 36wkGA. Hence, the ratio was most 
strongly predictive when it was measured closest to the timing of the given event. 
Cut offs within the study cohort 
We generated data derived cut offs for the prediction of preeclampsia based on the ROC curve using 
the sFlt-1:PlGF ratio at 28 weeks (Figure 1B). The cut off of sFlt-1:PlGF ratio of 14.6 resulted in 38% 
sensitivity and 98% specificity. We repeated the primary analysis with the new cut offs (Table S7). 
The positive predictive values were 12.7% for all women and 20.6% and 6.7% for high risk and low 
risk women, respectively.  
Table S1. Raw data on screening for the primary outcomes by maternal risk status using the threshold of sFlt-1:PlGF ratio of >38 at 28 and 36wkGA. 
 28 wkGA, PE delivery<37 36 wkGA, PE severe 
Screening result All High risk Low risk All High risk Low risk 
True positive (n) 6 4 2 58 32 26 
False positive (n) 13 9 4 508 126 382 
False negative (n) 20 14 6 48 28 20 
True negative (n) 3950 745 3205 3162 522 2640 
 
  
Table S2. Raw data on screening for the primary outcomes using the threshold of sFlt-1:PlGF ratio of >85 at 28wkGA and >110 at 36wkGA (by maternal risk 
status). 
 28 wkGA, PE 
delivery<37 
36 wkGA, PE severe 
Screening result All All High risk Low risk 
True positive (n) 4 21 12 9 
False positive (n) 3 49 21 28 
False negative (n) 22 85 48 37 
True negative (n) 3960 3621 627 2994 
 
  
Table S3. Characteristics of composite high risk group* at 36 weeks of gestational age (n=195). 
Maternal characteristic or birth outcome High risk 36wkGA† 
sFlt-1:PlGF ratio >110 70 (36) 
Age≥40 years 6 (3.1) 
Body mass index ≥35 kg/m2 25 (13) 
Type 1 or type 2 diabetes mellitus 5 (2.6) 
Chronic hypertension 56 (29) 
Renal disease 7 (3.6) 
Uterine artery mean PI‡ (Doppler) highest decile 90 (46) 
Preeclampsia with severe features 41 (21) 
Preeclampsia without severe features 43 (22) 
Gestational hypertension 9 (4.6) 
Time from sampling to first onset of hypertension, weeks 0.86 (-2.1 to 2.6) 
Time from sampling to delivery, weeks 3.1 (2.0 to 4.1) 
sFlt-1:PlGF ratio by time from sampling to delivery  
   1st quartile (≤2.0 weeks) 110 (61 to 172) 
   2nd quartile (2.1 to 3.1 weeks) 95 (58 to 151) 
   3rd quartile (3.2 to 4.1 weeks) 67 (50 to 116) 
   4th quartile (≥4.2 weeks) 64 (46 to 85) 
Gestational age, weeks 39.4 (38.3 to 40.4) 
Birth weight, g 3140 (2820 to 3430) 
Birth weight, centile 33 (13 to 57) 
Small for gestational age 41 (21) 
Induction of labor 91 (47) 
Mode of delivery  
   Spontaneous vaginal 95 (49) 
   Assisted vaginal 37 (19) 
   Intrapartum caesarean 39 (20) 
   Pre-labor caesarean 24 (12) 
 
Data are expressed as median (IQR) or n (%) as appropriate.  
*Composite risk status at 36wkGA: high risk was defined as sFlt-1:PlGF ratio of >38 with maternal 
risk factors, or sFlt-1:PlGF ratio>110 irrespective of maternal risk factors. Time from sampling to first 
onset of hypertension is given for the 93 (48%) women who had preeclampsia or gestational 
hypertension. Among the 41 women who had severe preeclampsia, 30 (73%) had severe 
hypertension, 30 (73%) had proteinuria, 10 (24%) had low platelets (at median GA [IQR] = 39.4 [39.0 
to 40.1] weeks), 13 (32%) had elevated ALT (at median GA [IQR] = 39.3 [38.6 to 40.0] weeks), 14 
(34%) had elevated creatinine (at median GA [IQR] = 39.3 [37.6 to 40.4] weeks), one (2.4%) had 
pulmonary edema, and one (2.4%) had severe cerebral or visual symptoms. In 14 (34%) of 41 cases 
severe preeclampsia was superimposed. Sex and gestational age corrected birth weight percentiles 
were calculated using a population-based UK reference. Small for gestational age was defined as 
birth weight <10th percentile. Data for the variables included in the table were 100% complete within 
the composite high risk group. †wkGA denotes weeks of gestational age. ‡PI denotes pulsatility 
index. 
  
Table S4. Characteristics of low risk women* at 36 weeks of gestational age (n=2,660). 
Maternal characteristic or birth outcome Low risk 36wkGA† 
Age, years 30.1 (26.8 to 33.0) 
Body mass index, kg/m2 23.7 (21.7 to 26.6) 
Uterine artery mean PI‡ (Doppler), Z score -0.20 (-0.76 to 0.39) 
Preeclampsia with severe features 20 (0.8) 
Preeclampsia without severe features 20 (0.8) 
Gestational hypertension 47 (1.8) 
Time from sampling to first onset of hypertension, weeks 3.3 (1.3 to 4.4) 
Time from sampling to delivery, weeks 4.3 (3.3 to 5.0) 
Gestational age, weeks 40.6 (39.6 to 41.3) 
Birth weight, g 3490 (3195 to 3780) 
Birth weight, centile 45 (26 to 68) 
Small for gestational age 192 (7.2) 
Induction of labor 799 (30) 
Mode of delivery  
   Spontaneous vaginal 1323 (50) 
   Assisted vaginal 681 (26) 
   Intrapartum caesarean 453 (17) 
   Pre-labor caesarean 196 (7.4) 
   Missing 7 (0.3) 
 
Data are expressed as median (IQR) or n (%) as appropriate.  
*Low risk women at 36wkGA: defined as sFlt-1:PlGF ratio of ≤38 without maternal risk factors. Time 
from sampling to first onset of hypertension is given for the 87 (3.3%) women who had preeclampsia 
or gestational hypertension. Among the 20 women who had severe preeclampsia, 12 (60%) had 
severe hypertension, 12 (60%) had proteinuria, 3 (15%) had low platelets (at median GA [IQR] = 41.4 
[39.9 to 41.4] weeks), 5 (25%) had elevated ALT (at median GA [IQR] = 40.6 [38.9 to 41.1] weeks), 9 
(45%) had elevated creatinine (at median GA [IQR] = 41.1 [39.9 to 41.4] weeks), none had pulmonary 
edema, and 3 (15%) had severe cerebral or visual symptoms. Sex and gestational age corrected birth 
weight percentiles were calculated using a population-based UK reference. Small for gestational age 
was defined as birth weight <10th percentile. Data for the variables included in the table were 100% 
complete within the composite high risk group. †wkGA denotes weeks of gestational age. ‡PI 
denotes pulsatility index. 
  
Table S5. Area under the ROC curve for the secondary outcomes and sub-types of preeclampsia. 
 
 Outcome c statistic (95% CI) 
Measurement of sFlt-1:PlGF ratio at 28wkGA  
 Preeclampsia, onset of hypertension <37wkGA 0.70 (0.65 to 0.75) 
 Gestational hypertension, delivery <37wkGA 0.88 (0.85 to 0.92) 
 Gestational hypertension, onset of hypertension <37wkGA 0.49 (0.38 to 0.60) 
 Preeclampsia or gestational hypertension, onset of hypertension <37wkGA 0.66 (0.61 to 0.71) 
 De novo preeclampsia, delivery <37wkGA 0.80 (0.68 to 0.92) 
 Superimposed preeclampsia, delivery <37wkGA 0.78 (0.63 to 0.94) 
 Preeclampsia with renal dysfunction, delivery <37wkGA 0.92 (N/A to 1.00) 
 Preeclampsia with HELLP syndrome, delivery <37wkGA 0.83 (0.49 to 1.00) 
   
Measurement of sFlt-1:PlGF ratio at 36wkGA 
  Preeclampsia without severe features  0.76 (0.72 to 0.80) 
 Severe gestational hypertension  0.70 (0.59 to 0.81) 
 Any gestational hypertension  0.62 (0.56 to 0.68) 
 Any preeclampsia or gestational hypertension  0.76 (0.73 to 0.79) 
 De novo preeclampsia with severe features 0.83 (0.77 to 0.88) 
 Superimposed preeclampsia with severe features 0.78 (0.70 to 0.85) 
 Preeclampsia with renal dysfunction 0.66 (0.47 to 0.84) 
 Preeclampsia with HELLP syndrome 0.89 (0.81 to 0.97) 
 
HELLP denotes hemolysis, elevated liver enzymes and low platelets, wkGA denotes weeks of 
gestational age, ROC denotes receiver operating characteristic, CI denotes confidence interval. 
 
Table S6. Area under the ROC curve for the analysis of preeclampsia with severe features and sFlt-
1:PlGF ratio at 36wkGA, stratified by the tertile of per week increase in the sFlt1-PlGF ratio between 
the 28wkGA and 36wkGA measurements. 
 
 Tertile Total N c statistic (95% CI) 
 1 1223 0.54 (0.32 to 0.77) 
 2 1222 0.58 (0.33 to 0.83) 
 3 1221 0.66 (0.59 to 0.73) 
 Total 3666 0.82 (0.77 to 0.86) 
 
In total, 3,666 women had sFlt-1 and PlGF measurements available at 28wkGA and 36wkGA. ROC 
denotes receiver operating characteristic, CI denotes confidence interval, wkGA denotes weeks of 
gestational age. P-value from the Chi-square test for the equality of the three c statistics = 0.52. 
  
Table S7. Screening statistics for the primary outcomes by maternal risk status using the threshold of 
sFlt-1:PlGF ratio of >14.6 at 28 wkGA. 
 28 wkGA, PE delivery<37 
Screening statistic (95% CI) All High risk Low risk 
Sensitivity (%) 38.5 (19.8-57.2) 38.9 (16.4-61.4) 37.5 (4.0-71.0) 
Specificity (%) 98.3 (97.9-98.7) 96.4 (95.1-97.7) 98.7 (98.3-99.1) 
Positive predictive value (%) 12.7 (5.3-20.0) 20.6 (7.0-34.2) 6.7 (0.0-14.0) 
Negative predictive value (%) 99.6 (99.4-99.8) 98.5 (97.6-99.4) 99.8 (99.7-100.0) 
False positive rate (%) 1.7 (1.3-2.1) 3.6 (2.3-4.9) 1.3 (0.92-1.7) 
False negative rate (%) 61.5 (42.8-80.2) 61.1 (38.6-83.6) 62.5 (29.0-96.0) 
Positive likelihood ratio 22.1 (12.9-37.9) 10.9 (5.5-21.6) 28.7 (11.2-73.6) 
Negative likelihood ratio  0.63 (0.46-0.85) 0.63 (0.44-0.92) 0.63 (0.37-1.08) 
 
  
 Figure S1. Venn diagram describing the condition of women who had pre-eclampsia with severe 
features (n=106). 
The total number of women having each severe feature of preeclampsia is given in brackets. 
Cerebral Visual denotes severe cerebral or visual disturbances. Proteinuria (n=72) and pulmonary 
oedema (n=2) are omitted from the diagram and both of these overlap with at least one other 
feature. 
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Figure S2. Receiver operating characteristic (ROC) curve analysis of the continuous sFlt-1:PlGF ratio 
at 28wkGA and primary outcome, stratified by A. high risk of preeclampsia, area under the ROC 
curve (95% CI) is 0.77 (0.64-0.89), and B. low risk, area under the ROC curve (95% CI) is 0.79 (0.64-
0.94). 
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Figure S3. Receiver operating characteristic (ROC) curve analysis of the continuous sFlt-1:PlGF ratio 
at 36wkGA and primary outcome, stratified by A. high risk of preeclampsia, area under the ROC 
curve (95% CI) is 0.76 (0.70-0.82), and B. low risk of preeclampsia, area under the ROC curve (95% CI) 
is 0.82 (0.75-0.89). 
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Figure S4. Receiver operating characteristic (ROC) curve analysis of the continuous sFlt-1:PlGF ratio 
at 28wkGA and secondary outcomes. Area under the ROC curve (95% CI) is given after the outcome. 
A. Preeclampsia, onset of hypertension <37wkGA, 0.70 (0.65-0.75). B. Gestational hypertension, 
delivery <37wkGA, 0.88 (0.85-0.92). C. Gestational hypertension, onset of hypertension <37wkGA, 
0.49 (0.38-0.60). D. Preeclampsia or gestational hypertension, onset of hypertension <37wkGA, 0.66 
(0.61-0.71).  
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Figure S5. Receiver operating characteristic (ROC) curve analysis of the continuous sFlt-1:PlGF ratio 
at 36wkGA and secondary outcomes. Area under the ROC curve (95% CI) is given after the outcome. 
A. Preeclampsia without severe features, 0.76 (0.72-0.80). B. Severe gestational hypertension, 0.70 
(0.59-0.81). C. Any gestational hypertension, 0.62 (0.56-0.68). D. Any preeclampsia or gestational 
hypertension, 0.76 (0.73-0.79).  
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Figure S6. Receiver operating characteristic (ROC) curve analysis of the continuous sFlt-1:PlGF ratio 
at 28wkGA and A. de novo preeclampsia with delivery <37wkGA, area under the ROC curve (95% CI) 
is 0.80 (0.68-0.92), and B. superimposed preeclampsia with delivery <37wkGA, area under the ROC 
curve (95% CI) is 0.78 (0.63-0.94).  
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Figure S7. Receiver operating characteristic (ROC) curve analysis of the continuous sFlt-1:PlGF ratio 
at 36wkGA and A. de novo preeclampsia with severe features, area under the ROC curve (95% CI) is 
0.83 (0.77-0.88), and B. superimposed preeclampsia with severe features, area under the ROC curve 
(95% CI) is 0.78 (0.70-0.85).  
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Figure S8. Receiver operating characteristic (ROC) curve analysis of the continuous sFlt-1:PlGF ratio 
at 28wkGA and primary outcome with A. renal dysfunction, area under the ROC curve (95% CI) is 
0.92 (N/A-1.00), B. HELLP syndrome, 0.83 (0.49-1.00).  
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Figure S9. Receiver operating characteristic (ROC) curve analysis of the continuous sFlt-1:PlGF ratio 
at 36wkGA and preeclampsia with A. renal dysfunction, area under the ROC curve (95% CI) is 0.66 
(0.47-0.84), B. HELLP syndrome, 0.89 (0.81-0.97). 
 
 Figure S10. Relative risk of (i) preeclampsia leading to preterm birth and (ii) preeclampsia with 
severe features, comparing women in the top decile of sFlt1:PlGF ratio against all other women. Cut-
off points for the top decile of sFlt1:PlGF ratio are 13.30 at 20wkGA, 6.90 at 28wkGA and 49.82 at 
36wkGA. The 36wkGA measurement was not analyzed in relation to preterm preeclampsia. 
 
